February 1, 2007 -- AstraZeneca paid $150 million to buy an anti-viral biotech called Arrow Therapeutics; the company will also cut 3,000 jobs; Pfizer will buy BioRexis Pharma to acquire its diabetes drug candidates; Affymax received a $10 million payment from its partner Takeda Pharma; Ligand slashed its employee headcount by 67%; Aastrom received Orphan Drug designation for use of its stem cell technology; Metabasis completed enrollment in a Phase IIb trial of a diabetes drug; GenVec signed a three-year contract with the DHS to develop a vaccine for foot and mouth disease; Hollis-Eden reported the gorvernment put off its decision to buy Neumune for the BioShield stockpile for another month; Gilead climbed 11% after reporting a very strong fourth quarter; but Sepracor sank another 4% after losing 5% yesterday. The Centient Biotech 200™ shot 40 points higher to 4082, an increase of .99%. More details...
